Compare Sasol Ltd. American Depositary Shares (SSL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sasol Ltd. American Depositary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sasol Ltd. American Depositary Shares trades at $15.79 (market cap $10.06B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Sasol Ltd. American Depositary Shares is the larger of the two by market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sasol Ltd. American Depositary Shares for 2 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SSL | SYRE | |
|---|---|---|
Market Cap | $10.06B | $7.35B |
Volume | 1,082,782 | 1,624,631 |
Sector | Basic Materials | Health |
52-Week High | $15.63 | $108.92 |
52-Week Low | $5.33 | $22.18 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $13.79B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sasol (SSL) trades at $15.58, up 1.83% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected revenue growth from $249.1B in 2025 to $272.1B in 2026. Recent developments include a sustainable aviation fuel agreement with White Desert and board changes, while the CFO's stock sales warrant monitoring.
SSL presents a compelling value opportunity with attractive valuation multiples (P/E 13.74, EV/EBITDA 5.45) and 73% analyst buy ratings. However, risks include negative cash flow trends and high RSI levels suggesting potential overbought conditions. The stock's upside depends on continued operational improvements and commodity market stability.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sasol Ltd. American Depositary Shares
Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
